Suki Siti Zaleha, Zuhdi Ahmad Syadi Mahmood, Yahya Abqariyah, Zaharan Nur Lisa
Department of Pharmacology, Universiti Malaya, Kuala Lumpur, Malaysia.
Centre of Preclinical Science Studies (Pharmacology), Faculty of Dentistry, Universiti Teknologi MARA, Selangor, Malaysia.
J Geriatr Cardiol. 2025 Feb 28;22(2):237-245. doi: 10.26599/1671-5411.2025.02.004.
To examine 5-year trends and variations in dual antiplatelet therapy (DAPT) prescription among multiethnic Malaysian patients aged 60 years and older.
Using the Malaysian National Cardiovascular Disease-Acute Coronary Syndrome (NCVD-ACS) registry, DAPT 5-year temporal trends prescribing patterns at discharge were examined. Multivariate logistic regression was used to calculate the adjusted odds ratio (aOR) of DAPT prescription. The 1-year all-cause mortality by Cox proportional hazard regression model (adjusted hazard ratio, aHR) using inverse proportional weighting covariates adjustment was performed to assess DAPT prognostic impacts.
Data of patients aged 60 years and older were extracted from 2013 to 2017 ( = 3718, mean age: 68 ± 6.74 years, men: 72%, and Malay ethnicity: 43%). The majority of patients were diagnosed with non-ST-segment elevation acute coronary syndrome (63%), predisposed hypertension (76%) and were overweight (74%), while only 35% of patients underwent percutaneous coronary intervention. Over the five years, there was a significant increasing trend in DAPT prescriptions ( < 0.001), with the aspirin-clopidogrel combination being the most common. Aspirin-ticagrelor prescriptions have also increased over the years. Variations in DAPT prescriptions were observed based on patient characteristics. Patients who underwent percutaneous coronary intervention were more likely to be prescribed DAPT in general (aOR = 2.53, 95% CI: 1.95-3.28, < 0.001) and aspirin-ticagrelor specifically (aOR = 7.76, 95% CI: 5.65-10.68, < 0.001). Patients with chronic lung disease (aOR = 0.62, 95% CI: 0.42-0.92, = 0.02) and a history of angina within two weeks (aOR = 0.69, 95% CI: 0.56-0.85, < 0.001) were approximately 30% less likely to be prescribed DAPT. Approximately 15% of 1-year all-cause mortality were reported. Older patients prescribed DAPT showed significantly higher survival rates than those who were not (aHR < 1.0, < 0.001). Aspirin-ticagrelor was associated with higher survival rates than aspirin-clopidogrel (aHR = 0.21, 95% CI: 0.11-0.40, < 0.001).
Despite the optimal prescription rate and variation of DAPT in the older Malaysian population, there is room for investigation and improvement in the prescription of newer DAPT combinations that have been suggested to improve patient survival.
研究60岁及以上马来西亚多民族患者双联抗血小板治疗(DAPT)处方的5年趋势及差异。
利用马来西亚国家心血管疾病-急性冠状动脉综合征(NCVD-ACS)登记处的数据,研究出院时DAPT的5年时间趋势和处方模式。采用多因素逻辑回归计算DAPT处方的调整优势比(aOR)。使用逆概率加权协变量调整的Cox比例风险回归模型进行1年全因死亡率分析,以评估DAPT的预后影响。
提取了2013年至2017年60岁及以上患者的数据(n = 3718,平均年龄:68±6.74岁,男性:72%,马来族裔:43%)。大多数患者被诊断为非ST段抬高型急性冠状动脉综合征(63%),患有高血压(76%)且超重(74%),而仅35%的患者接受了经皮冠状动脉介入治疗。在这五年中,DAPT处方有显著增加趋势(P < 0.001),阿司匹林-氯吡格雷组合最为常见。多年来,阿司匹林-替格瑞洛处方也有所增加。根据患者特征观察到DAPT处方存在差异。一般而言,接受经皮冠状动脉介入治疗的患者更有可能被开具DAPT处方(aOR = 2.53,95%置信区间:1.95 - 3.28,P < 0.001),尤其是阿司匹林-替格瑞洛(aOR = 7.76,95%置信区间:5.65 - 10.68,P < 0.001)。患有慢性肺病的患者(aOR = 0.62,95%置信区间:0.42 - 0.92,P = 0.02)和两周内有心绞痛病史的患者(aOR = 0.69,95%置信区间:0.56 - 0.85,P < 0.001)开具DAPT处方的可能性约低30%。报告的1年全因死亡率约为15%。开具DAPT处方的老年患者生存率显著高于未开具的患者(aHR < 1.0,P < 0.001)。阿司匹林-替格瑞洛与比阿司匹林-氯吡格雷更高的生存率相关(aHR = 0.21,95%置信区间:0.11 - 0.40,P < 0.001)。
尽管马来西亚老年人群中DAPT的处方率和差异情况较为理想,但对于已被建议可提高患者生存率的新型DAPT组合的处方,仍有研究和改进的空间。